Cytotoxicity against cancer cells

Cytotoxicity against cancer cells is a phenotypic outcome or biological process rather than a specific molecular target like a receptor or enzyme. It describes the capacity of a therapeutic agent, chemical compound, or immune effector cell—such as Cytotoxic T Lymphocytes (CTLs) or Natural Killer (NK) cells—to induce death in malignant cells [1, 2, 3]. In pharmacological research, this effect is fundamental for evaluating the efficacy of antineoplastic agents and is typically quantified using in vitro viability assays or in vivo tumor regression models [6, 8, 11]. Mechanisms driving this cytotoxicity vary widely, including direct DNA damage, inhibition of mitotic spindles, or the delivery of lethal hits via perforin-dependent membrane pore formation [10, 13]. A critical challenge in oncology is achieving 'selective cytotoxicity,' where tumor cells are targeted while sparing healthy, rapidly dividing cells [4, 5]. Consequently, treatments that exhibit high potency often carry significant safety concerns, such as myelosuppression and organ-specific toxicities, due to the lack of absolute specificity for cancer-specific pathways [5, 11].

Other names

Anticancer activityAnti-tumor activityTumor cell lysisCell killing activityCytotoxic effectAntineoplastic activitySelective cytotoxicity

Drugs and immune cells induce cytotoxicity through diverse mechanisms including DNA cross-linking, intercalation, microtubule stabilization, and the release of cytotoxic granules containing perforin and granzymes that trigger apoptotic cascades in target cells.